Lead Sponsor

Centro de estudios en Cardiologia Intervencionista

Collaborators

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

•Patient signing informed consent after receiving extensive written and oral information about the trial,
•Older than 18 years,
•Agreement to have a control examination done after six months,
•Patients with angina pectoris symptoms (CCS stages i-IV, unstable angina pectoris Braunwald B and C) and patients with documented silent ischemia;
•Patients with one or more de novo lesions which all are to be dilated in the same session;
•Target vessel diameter of 2.5 to 4.0 mm

•Female patients of child bearing age with pregnancy suspicion(a pregnancy test will be done in this cases)
•Acute myocardial infarction (Q wave or non Q wave ) with documented CK levels more than 2 fold higher than the normal values in the preceding 72 hours ,
•Substantially calcified lesion precluding successful pre dilatation,
•Ejection Fraction less than 35%,
•Patient with previous PCI with one DES,
•Target lesion \< 2.5 mm
•Coagulopathy or clotting disorders, leucopenia anemia or thrombocytopenia,
•Allergy, hypersensitivity or adverse reaction to paclitaxel,
•Intolerance to the clopidogrel, Ticlopidine or Aspirin or unable to receive clopidogrel for one year,
•Active duodenal or gastric ulcer,
•Life Expectancy less than 1 year,
•Patient with LM disease (\>50%)

Related studies

NCT07660419 · Coronary Artery Disease (CAD), Coronary Stenosis

NCT06779630 · Coronary Artery Disease

NCT07565805 · Coronary Artery Disease (CAD)

NCT07560436 · Heart Failure With Preserved Ejection Fraction (HFPEF), Coronary Artery Disease

NCT07324720 · Coronary Artery Disease

A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent